A detailed history of Barclays PLC transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Barclays PLC holds 13,239 shares of ORMP stock, worth $31,376. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,239
Previous 13,239 -0.0%
Holding current value
$31,376
Previous $32,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 15, 2024

SELL
$1.71 - $2.57 $8,835 - $13,279
-5,167 Reduced 28.07%
13,239 $30,000
Q3 2023

Nov 07, 2023

BUY
$2.51 - $3.55 $12,969 - $18,342
5,167 Added 39.03%
18,406 $47,000
Q2 2023

Aug 03, 2023

SELL
$2.12 - $4.47 $15,709 - $33,122
-7,410 Reduced 35.89%
13,239 $47,000
Q1 2023

May 04, 2023

SELL
$1.93 - $13.1 $36,918 - $250,589
-19,129 Reduced 48.09%
20,649 $45,000
Q4 2022

Feb 13, 2023

BUY
$5.88 - $12.03 $107,221 - $219,367
18,235 Added 84.64%
39,778 $478,000
Q3 2022

Nov 03, 2022

BUY
$4.6 - $9.91 $7,930 - $17,084
1,724 Added 8.7%
21,543 $140,000
Q2 2022

Aug 12, 2022

SELL
$3.72 - $9.0 $24,217 - $58,590
-6,510 Reduced 24.73%
19,819 $90,000
Q1 2022

May 16, 2022

SELL
$8.19 - $13.89 $233,849 - $396,601
-28,553 Reduced 52.03%
26,329 $227,000
Q4 2021

Feb 14, 2022

BUY
$12.98 - $29.75 $308,145 - $706,265
23,740 Added 76.23%
54,882 $783,000
Q3 2021

Nov 09, 2021

SELL
$12.13 - $23.82 $64,762 - $127,174
-5,339 Reduced 14.64%
31,142 $685,000
Q2 2021

Aug 13, 2021

BUY
$8.34 - $14.59 $133,423 - $233,410
15,998 Added 78.1%
36,481 $488,000
Q1 2021

May 13, 2021

BUY
$4.22 - $11.33 $70,305 - $188,757
16,660 Added 435.78%
20,483 $208,000
Q4 2019

Feb 10, 2020

SELL
$2.43 - $5.74 $90,821 - $214,532
-37,375 Reduced 90.72%
3,823 $20,000
Q3 2019

Nov 14, 2019

BUY
$2.88 - $3.96 $34 - $47
12 Added 0.03%
41,198 $131,000
Q3 2017

Nov 14, 2017

BUY
$7.74 - $10.78 $318,779 - $443,985
41,186
41,186 $409,000

Others Institutions Holding ORMP

About ORAMED PHARMACEUTICALS INC.


  • Ticker ORMP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,100
  • Market Cap $92M
  • Description
  • Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...
More about ORMP
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.